Advanced search×

TAK-652, a novel CCR5 inhibitor, has favourable drug interactions with other antiretrovirals in vitro.

Cécile L CL Tremblay, Françoise F Giguel, Ting-Chao TC Chou, Huajin H Dong, Katsunori K Takashima, and Martin S MS Hirsch

Antivir Ther 10(8):967-8 (2005) PMID 16430202

Version: za2963e q8za0 q8zbf q8zc0 q8zd8 q8zea q8zfb q8zga
Buy PDF

Similar articles you may find interesting…

  1. mTOR, p70S6K, AKT and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Teresa Gagliano, Mariaenrica Bellio, and Maria Chiara Zatelli

    Endocr Relat Cancer (2013) PMID 23653462

    We search for possible markers of mTOR inhibitors efficacy, that may help in identifying the patients that may benefit from mTOR inhibitors treatment, sparing them from ineffective therapy. We found that NVP-BEZ235 is twice as potent as Everolimus in reducing cell viability and activating apoptosis...
    Buy PDF
  2. Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo.
    Hong-Lei Jiang, Jun-Zhe Jin, and Jian Liang

    Mol Biol Rep (2013) PMID 23649759

    We investigated the potential anti-human c-Met-deficient hepatocellular carcinoma effects of Celastrol, a novel triterpene, and its combination with PHA. Human hepatocellular carcinoma cells BEL-7402 (c-Met-positive) and Huh7 (c-Met-deficient) were treated with different dose of PHA with or without...
    Buy PDF
  3. Phase I/II RAF kinase inhibitors in cancer therapy.
    Samra Turajlic, Zohra Ali, and James Larkin

    Expert Opin Investig Drugs (2013) PMID 23642225

    Aberrant activation of RAF signalling is a frequent finding in human cancers. BRAF is the only RAF family member that is commonly mutated, whilst CRAF and ARAF play important roles in the signal transduction from mutant RAS. BRAF-specific inhibitors have been more effective in the treatment of BRAF-...
    Buy PDF